Resmetirom Shows Promise in Preventing Liver Cancer in Fatty Liver Disease Patients
A recent study published in the journal Hepatology reveals that Resmetirom, a drug approved by the U.S. Food and Drug Administration (FDA) for treating metabolic dysfunction associated fatty liver disease (MAFLD), may also help prevent liver cancer. Conducted by researchers from the University of Hong Kong, the study found that Resmetirom not only reduces liver fat and fibrosis but also suppresses liver cancer linked to fatty liver disease. The research identified the Midkine (MDK) gene and its receptor as a significant cancer-promoting pathway, which Resmetirom appears to modulate. The study highlights the potential of Resmetirom to improve liver metabolism, reduce liver fat, and reshape the immune microenvironment, suggesting a new prevention-oriented treatment model for high-risk patients. 
